Market Place
Sourcing Support
Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific
27 Jan 2023 //
BIOSPACE
Braxia Scientific Reports Q2 2023 Financial Results
29 Nov 2022 //
PRNEWSWIRE
Braxia Scientific Announces Voting Results from the Annual General
01 Nov 2022 //
PRNEWSWIRE
KetaMD Expands Access to Breakthrough Ketamine Therapy
04 Oct 2022 //
PRNEWSWIRE
Braxia Scientific Announces Board Appointment
21 Sep 2022 //
PRNEWSWIRE
Braxia Scientific Announces Court Approval of Class Action Settlement in Canada
16 Sep 2022 //
PRNEWSWIRE
Braxia Scientific Launches KetaMD in Florida
12 Sep 2022 //
PRNEWSWIRE
Braxia Scientific to Present at H.C. Wainwright Global Investment Conference
09 Sep 2022 //
PRNEWSWIRE
Braxia Scientific Reports Q1 2023 Financial Results
29 Aug 2022 //
PRNEWSWIRE
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD
03 Aug 2022 //
PRNEWSWIRE
Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
29 Jul 2022 //
PRNEWSWIRE
Braxia Scientific Bolsters Leadership with Strategic Hires; Adds leadership
27 Jul 2022 //
PRNEWSWIRE
Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright Conference
24 Jun 2022 //
PRNEWSWIRE
Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access
15 Jun 2022 //
PRNEWSWIRE
Braxia Scientific Presents Positive Preliminary Findings from PII Trial
02 Jun 2022 //
PRNEWSWIRE
Braxia Scientific Gets Health Canada SAP Approval in Psilocybin-Assisted Therapy
20 May 2022 //
PRNEWSWIRE
Braxia Scientific to Present at H.C. Wainwright Global Investment Conference
19 May 2022 //
PRNEWSWIRE
Braxia Scientific CEO to Speak at American Psychiatric Association Meeting
18 May 2022 //
PRNEWSWIRE
Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada
13 Apr 2022 //
PRNEWSWIRE
Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada
11 Apr 2022 //
PRNEWSWIRE
Braxia Scientific CEO and CMO, Invited to Speak as Experts
01 Apr 2022 //
PRNEWSWIRE
Braxia Scientific Reports Q3 2022 Financial Results
01 Mar 2022 //
PRNEWSWIRE
Braxia Provides Update on Large Proprietary Dataset for Ketamine and Psilocybin
31 Jan 2022 //
PRNEWSWIRE
Braxia Achieves Milestone as Landmark Psilocybin Clinical Trial Commences
14 Dec 2021 //
PRNEWSWIRE
Braxia Announces Voting Results from Annual General Meeting of Shareholders
29 Oct 2021 //
PRNEWSWIRE
Journal of the Royal Society of Medicine Publishes COVID-19 Suicide Research
21 Oct 2021 //
PRNEWSWIRE
Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion
14 Oct 2021 //
PRNEWSWIRE
Braxia Scientific Reports Encouraging Results of Ketamine Study
30 Sep 2021 //
PRNEWSWIRE
Braxia Scientific Reports First Quarter 2022 Financial Results
30 Aug 2021 //
PRNEWSWIRE
Braxia Scientific Comments on US Class Action
27 Aug 2021 //
PRNEWSWIRE
Braxia Scientific to Commence Landmark Clinical Trial
27 Aug 2021 //
PRNEWSWIRE
Braxia Announces Participation at H.C. Wainwright Global Investment Conference
17 Aug 2021 //
PRNEWSWIRE
Braxia Scientific to Participate at Canaccord Genuity 2021 Growth Conference
06 Aug 2021 //
PRNEWSWIRE
Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter
02 Aug 2021 //
NEWSWIRE
